MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

ACTIVE NOT RECRUITING

NCT01415752·PHASE2·Eastern Cooperative Oncology Group·373 enrolled

rituximabBendamustinebortezomiblenalidomide

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

ACTIVE NOT RECRUITING

NCT01318317·PHASE1 / PHASE2·City of Hope Medical Center·8 enrolled

Autologous Hematopoietic Stem Cell TransplantationFilgrastimGenetically Engineered Lymphocyte TherapyLaboratory Biomarker AnalysisPeripheral Blood Stem Cell Transplantation+2 more

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

ACTIVE NOT RECRUITING

NCT01199562·City of Hope Medical Center·153 enrolled

infection prophylaxis and managementlaboratory biomarker analysisflow cytometryDNA analysisRNA analysis+7 more

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

ACTIVE NOT RECRUITING

NCT00877214·PHASE3·Jurgen Barth·1272 enrolled

RituximabRituximab / observation

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

ACTIVE NOT RECRUITING

NCT00544115·PHASE2·City of Hope Medical Center·260 enrolled

busulfancyclophosphamidecyclosporineetoposidefludarabine phosphate+8 more

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

ACTIVE NOT RECRUITING

NCT00641381·PHASE1·City of Hope Medical Center·25 enrolled

carmustinecyclophosphamideetoposidepharmacological studyautologous hematopoietic stem cell transplantation+1 more

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

ENROLLING BY INVITATION

NCT07168486·PHASE1·University of Maryland, Baltimore·15 enrolled

CD19.20.22 CAR T cellsFludarabine and Cyclophosphamide

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

WITHDRAWN

NCT05936229·PHASE1 / PHASE2·Fred Hutchinson Cancer Center

Interferon Beta-1AX-Ray ImagingEchocardiographyMultigated Acquisition ScanComputed Tomography+6 more

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

TERMINATED

NCT06343376·PHASE1·Roswell Park Cancer Institute·1 enrolled

BiopsyBiospecimen CollectionBone Marrow AspirationBone Marrow BiopsyComputed Tomography+7 more

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

TERMINATED

NCT06256484·PHASE1·Atara Biotherapeutics·1 enrolled

ATA3219

Preliminary Assessment of [18F]BL40 in PET/CT Scans

UNKNOWN

NCT06224309·British Columbia Cancer Agency·30 enrolled

18F-BL40 PET/CT18F-FDG PET/CTRoutine Blood Draw - Phase 1 only

Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim

UNKNOWN

NCT04947618·Centre Hospitalier Universitaire de Nīmes·400 enrolled

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

COMPLETED

NCT06004167·NA·Massachusetts General Hospital·10 enrolled

Adaptive Bridging Radiation Therapy (ABRT)

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

TERMINATED

NCT06106841·PHASE1 / PHASE2·Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·19 enrolled

400mg of TQB3909 tablets600mg of TQB3909 tablets

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

COMPLETED

NCT05665530·PHASE1·Prelude Therapeutics·86 enrolled

PRT2527ZanubrutinibVenetoclax

Evaluating Different Doses of Orelabrutinib in MCL

UNKNOWN

NCT05978739·PHASE2·InnoCare Pharma Inc.·40 enrolled

Orelabrutinib High doseOrelabrutinib Low dose

A Food Effect Study of LP-168 Tablets in Healthy Subjects

COMPLETED

NCT05917964·PHASE1·Guangzhou Lupeng Pharmaceutical Company LTD.·22 enrolled

LP-168 tablet

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

TERMINATED

NCT05588440·PHASE1 / PHASE2·Oncternal Therapeutics, Inc·9 enrolled

ONCT-808Bridging Therapy

Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma

WITHDRAWN

NCT04231734·NA·Weill Medical College of Cornell University

Ketogenic Diet

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

TERMINATED

NCT05788289·PHASE2·Memorial Sloan Kettering Cancer Center·4 enrolled

TafasitamabLenalidomide

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

WITHDRAWN

NCT05431179·PHASE3·Oncternal Therapeutics, Inc

ZilovertamabIbrutinibPlacebo

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

TERMINATED

NCT05720052·PHASE1 / PHASE2·MingSight Pharmaceuticals, Inc·8 enrolled

MS-553

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

COMPLETED

NCT05694364·PHASE1·H. Lee Moffitt Cancer Center and Research Institute·3 enrolled

FludarabineCyclophosphamidePRGN-3007

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

COMPLETED

NCT05564052·PHASE2·Janssen Research & Development, LLC·36 enrolled

IbrutinibLenalidomideRituximabBortezomib

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

WITHDRAWN

NCT05934097·PHASE1·Fate Therapeutics

FT596CyclophosphamideDoxorubicinVincristinePrednisone+2 more

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

TERMINATED

NCT05611853·PHASE1 / PHASE2·BioNova Pharmaceuticals (Shanghai) LTD.·9 enrolled

BN301

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

WITHDRAWN

NCT04635683·PHASE1·Yazeed Sawalha

LenalidomideUblituximabUmbralisib

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

UNKNOWN

NCT05888701·University of Milano Bicocca·30 enrolled

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

UNKNOWN

NCT05444322·EARLY_PHASE1·He Huang·18 enrolled

RD14-01 cell infusion

← PreviousPage 8 of 41Next →